David D. Chang - 14 Mar 2025 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Signature
/s/Earl Douglas, Attorney-in-Fact
Issuer symbol
ALLO
Transactions as of
14 Mar 2025
Net transactions value
-$91,469
Form type
4
Filing time
18 Mar 2025, 17:30:50 UTC
Previous filing
05 Feb 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Sale $91,469 -46,668 -0.88% $1.96 5,276,569 14 Mar 2025 Direct F1, F2, F3
holding ALLO Common Stock 856,044 14 Mar 2025 See footnote F4
holding ALLO Common Stock 856,044 14 Mar 2025 See footnote F5
holding ALLO Common Stock 1,201,108 14 Mar 2025 See footnote F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in one transaction at a single price point of $1.96. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at the price set forth above.
F3 Includes 6000 shares of the Issuer's common stock acquired by the reporting person on March 14, 2025 pursuant to an employee stock purchase program.
F4 Securities held in the name of the RTC 2019 Trust dated October 1, 2019.
F5 Securities held in the name of the JEC 2019 Trust dated October 1, 2019.
F6 Securities held in the name of the Chang 2006 Family Trust